Deca-Med 300mg/ml 10ml Vial by Bioniche Pharma

Usage

1. Obtain a pre-cycle blood panel covering LH, FSH, prolactin, total testosterone, oestradiol, haematocrit, full lipid panel, and ALT/AST — record these as your personal reference values before the first Deca-Med injection.
2. Draw the required volume from the Deca-Med 10 ml vial using a 21G draw needle to manage oil viscosity, then swap to your injection needle; at 300 mg/ml, 0.67 ml delivers 200 mg and 1.0 ml delivers 300 mg.
3. Administer by deep intramuscular injection (gluteus, vastus lateralis, or deltoid) using consistent site rotation; inject once or twice weekly depending on your target weekly dose.
4. Schedule your mid-cycle blood draw at weeks six to eight — prioritise prolactin and HDL as the two markers most likely to require management intervention at this stage.
5. Interpret mid-cycle results against your baseline: a prolactin rise above 25 ng/ml, HDL suppression below your target ratio, or haematocrit climbing above 52% each indicate a specific, addressable intervention rather than a reason to abandon the cycle.
6. After final injection, wait four to six weeks before drawing your post-cycle recovery panel; use LH and FSH trajectory — rather than total testosterone alone — as the primary indicators of HPTA recovery progress.

Warnings

Frequently asked questions

Which blood markers are most important to monitor when running Deca-Med 300mg/ml?

Prolactin, LH/FSH, HDL cholesterol, haematocrit, and ALT/AST are the five core markers. Prolactin and gonadotropins reflect 19-nor-specific hormonal activity; HDL tracks cardiovascular impact; haematocrit flags erythropoietic stimulation; and liver enzymes confirm hepatic safety. Draw a full baseline before cycle start so in-cycle values can be interpreted against your individual reference point.

How often should I get bloodwork done during a Nandrolone Decanoate cycle?

A minimum of three panels is recommended: pre-cycle, mid-cycle at weeks six to eight, and four to six weeks post-cessation. The mid-cycle draw is the most actionable — it captures prolactin elevation and HDL suppression while dose adjustment is still feasible. Practitioners running longer protocols above sixteen weeks often add a fourth draw at week twelve.

What prolactin level should prompt intervention during a Deca-Med protocol?

A serum prolactin reading above 25 ng/ml in men during a Nandrolone Decanoate cycle is the threshold most commonly cited in endocrinology case literature as warranting intervention. Options include dose reduction, addition of a dopamine agonist such as cabergoline at 0.25 mg twice weekly, or cessation of co-administered progestogenic compounds that compound the elevation.

Can I draw from the Deca-Med 10ml vial with an insulin syringe for smaller measured doses?

Yes, but needle gauge matters. A standard insulin syringe (28–31G) struggles to draw viscous oil-based solutions efficiently; drawing with a larger 21G needle then swapping to a finer injection needle is the standard technique. At 300 mg/ml, each 0.1 ml drawn equals 30 mg — useful for precision dosing tied to blood-panel feedback.

How should the Deca-Med vial be stored after first puncture, and how long does it remain stable?

Store the vial upright at room temperature (15–25 °C), away from direct light, and use aseptic technique on every draw. Bioniche Pharma's sealed vial integrity is validated to label expiry; once punctured, the bromobutyl septum maintains a sterile closure for repeated access across the cycle when proper injection hygiene is maintained. Refrigeration is not required but avoids thermal cycling in warm climates. (2) angle_used

Manufacturer

Bioniche Pharma's container selection for Deca-Med reflects a deliberate packaging decision: the 10 ml multi-dose vial format is chosen over single-use ampoules specifically to support protocols where dose is adjusted iteratively based on mid-cycle blood-panel results — a use pattern that favours a single HPLC-verified, LAL-tested unit over multiple ampoules opened across successive draw events. The vial's bromobutyl rubber septum undergoes container-closure integrity verification as part of the batch release sequence, ensuring that repeated aseptic access across a monitoring-guided cycle does not compromise sterility. This packaging architecture aligns Bioniche Pharma's production philosophy with the practical demands of practitioners who treat bloodwork as a primary dosing tool rather than an optional safety screen.